Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors
Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Dimopoulos MA, Facon T, Usmani SZ, Mateos MV, Costa LJ. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors. JAMA Oncology 2020, 6: 1759-1765. PMID: 32970151, PMCID: PMC7516804, DOI: 10.1001/jamaoncol.2020.4338.Peer-Reviewed Original ResearchConceptsProgression-free survivalHigh-risk MMBackbone regimensRefractory MMHazard ratioMultiple myelomaClinical trialsSystematic reviewDerSimonian-Laird random-effects modelPhase 3 trialImproved response ratesPreferred Reporting ItemsRandom-effects modelCochrane riskSame regimenCytogenetic riskCochrane LibraryMeeting libraryI2 statisticImproved outcomesMAIN OUTCOMEThird investigatorCochran's QPatientsReporting ItemsEfficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis
Giri S, Aryal MR, Yu H, Grimshaw A, Pathak R, Huntington SP, Dhakal B. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis. Journal Of Geriatric Oncology 2020, 11: 1285-1292. PMID: 32513568, PMCID: PMC8721742, DOI: 10.1016/j.jgo.2020.05.013.Peer-Reviewed Original ResearchConceptsTransplant-ineligible patientsMultiple myelomaTreatment optionsPhase II/IIICumulative ranking (SUCRA) probabilitiesFirst-line treatmentHematopoietic cell transplantationTerms of efficacyRandom-effects modelEfficacious regimensFrailty biomarkersFrontline regimensThalidomide maintenanceEffective regimensGeriatric assessmentLine treatmentTreatment regimensCell transplantationMeeting libraryIndividual patientsToxicity profileRegimensPatientsSystematic reviewRanking probability